Session Name: Acute Myeloid Leukemia - Therapy, Excluding Transplantation
Session Date: Tuesday, December 9th, 2008 Presentation Time: 7:45 AM
Session Location: Moscone Center, Room 3020-3022-3024 - West
2008 ASH Annual Meeting - Poster Presentation
Title: Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense
Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients
with Relapsed/Refractory AML
Abstract: #1943, Poster Board # II-37
Session Date: Sunday, December 7th, 2008
Session Time: 6:00 PM - 8:00 PM
Session Location: Moscone Center, Hall A
AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel oncology drug target. The activity of AEG35156 is currently being explored, in combination, or as a monotherapy, in the following indications: acute myeloid leukemia, non-small cell lung cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study is being conducted with the financial and scientific support of the Leukemia and Lymphoma Society through their innovative Therapy Acceleration Program.
About Aegera Therapeutics Inc.
Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. In addition to AEG35156, Aegera has three additional programs in clinical development for the treatment of cancer and neuropathic pain. Details
|SOURCE AEGERA THERAPEUTICS INC.|
Copyright©2008 PR Newswire.
All rights reserved